Closely held JVP Labs is developing the only non-invasive, real-time cardiac filling pressure monitoring solution for managing congestive heart failure (CHF) patients—for both in the hospital and at home.

Closely held Longhorn Vaccines and Diagnostics is developing peptide vaccines and monoclonal antibodies aimed at preventing and reducing the global burden of medical conditions caused by key bacterial toxins, including...

Closely held Tasman Therapeutics is shifting the treatment landscape for treatment-resistant depression (TRD) with its registered, proprietary formulation—a first-of-its-kind, oral extended-release ketamine tablet.

Arch Biopartners (TXSV:ARCH; QTCQB:ACHFF) is at the forefront of developing breakthrough therapies to combat acute kidney injury (AKI) and prevent organ damage. By targeting the dipeptidase-1 (DPEP1) inflammation...

Vivos Therapeutics (NASDAQ:VVOS) is developing and commercializing innovative diagnostic and treatment methods for adult and pediatric patients suffering from sleep-related breathing disorders, including severe...

Closely held Future Fields is spearheading the world’s first synthetic biology system with an innovative transgenic bug-based approach—leveraging fruit flies to combine genetic engineering with insect farming to unlock...

Closely-held Evergen, formerly RTI Surgical, is advancing innovative medical solutions across the cardiac, sports and orthopedics, plastic and reconstructive surgery, and neuro-spine clinical segments as the only...

Closely-held MOBILion Systems is redefining analytical characterization through its next-generation separation science platform that is integrated with high-resolution mass spectrometry to achieve unprecedented...

Closely-held VICO Therapeutics is developing antisense oligonucleotide (ASO) RNA modulating therapies for patients with severe genetic neurological diseases, including Huntington’s disease (HD) and spinocerebellar...

Closely-held ROMTech is combining cutting-edge innovation with advanced telemedicine technology, transforming rehabilitation, diagnostics, facilitating seamless remote patient-physician connections for at-home...

Closely-held GRIN Therapeutics, a Neurvati Neuroscience company, is advancing promising research and development of precision therapeutics for neurodevelopmental disorders, predominately affecting children from infancy...

Closely-held Creyon Bio is developing a faster, more cost-effective path to new medicines for rare and common diseases through the AI-enabled engineering of oligonucleotide-based therapies (OBMs) that deliver safe...